Search

Background: The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2–13 (and 14–15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom. Methods: End‐of‐season adjusted vaccine effectiveness (VE) estimates against sentinel primary‐care attendance for influenza‐like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders. Methods: Results In the mainland United Kingdom, end‐of‐season VE against all laboratory‐confirmed influenza for all those > 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: −6% to 54%). VE for those aged 18–64, who largely received cell‐based vaccines, was 47% (95% CI: 37%–56%). Overall VE for 2–17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%–76%). Conclusion: The paper provides evidence of moderate influenza VE in 2022/23. [ABSTRACT FROM AUTHOR]

Objectives: A successful response to the COVID‐19 pandemic requires achieving high levels of vaccine uptake. We tested whether directly contrasting the high efficacy of COVID‐19 vaccines with the lower efficacy of the annual flu vaccine would increase intentions to take a COVID‐19 vaccine. Design: A pre‐registered online study of 481 participants compared four information conditions: (1) no information; (2) COVID‐19 Vaccine Information Only; and COVID‐19 Vaccine Information combined with flu vaccine information suggesting either (3) 60% efficacy or (4) 40% efficacy; we measured COVID‐19 and flu vaccine intentions along with several other vaccine‐related variables. Methods: The Prolific platform was used to recruit 481 UK participants (64% female; aged between 18 and 85 years) who had been pre‐screened to have intermediate levels of vaccine hesitancy. After reading a short text (~200 words) about COVID‐19 vaccines, participants were asked about their vaccination intentions. Results: Providing information about the safety and efficacy of the new COVID‐19 vaccines resulted in vaccination intentions that were, on average, 0.39 standard deviations (SDs) higher than those in the no information condition; providing the same COVID vaccine efficacy information in the context of information about flu vaccine efficacy resulted in a further significant increase in vaccination intentions that were 0.68 SD higher than those in the no information condition. This positive contrast effect for the COVID‐19 vaccine was not associated with reduced flu vaccine intentions. Conclusions: Vaccination intentions can be strengthened through a simple messaging intervention that utilizes context effects to increase perceived response efficacy. [ABSTRACT FROM AUTHOR]